Figure 1 from Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer

Clinical outcomes in patients treated with elacestrant. A depicts the TTNT since elacestrant initiation in this cohort of patients with MBC and ESR1 mutation detected within 6 months prior to therapy start. B displays the TTD in this cohort, and C displays the OS. Vertical hash marks denote a censored patient event. CL, confidence limit.